Dt. Felson et al., THE EFFECT OF POSTMENOPAUSAL ESTROGEN THERAPY ON BONE-DENSITY IN ELDERLY WOMEN, The New England journal of medicine, 329(16), 1993, pp. 1141-1146
Background. Estrogen therapy prevents bone loss in postmenopausal wome
n who take it early in the postmenopausal period. The risk of fracture
is highest much later in life, however. We studied whether bone mass
in elderly women was affected by earlier estrogen use and how long wom
en needed to take estrogen for it to have a beneficial effect on bone
density later in life. Methods. In 1988 and 1989, we measured bone min
eral density at the femur, spine, shaft of the radius, and ultradistal
radius in 670 white women in the Framingham Study cohort (mean age, 7
6 years; range, 68 to 96). These women had been followed prospectively
through menopause and had been asked repeatedly about estrogen therap
y. After excluding women who began taking estrogen after a fracture, w
e investigated whether postmenopausal estrogen therapy affected bone d
ensity; in these analyses we adjusted for age, weight, height, cigaret
te smoking, physical activity, and age at menopause. Results. A total
of 212 women (31.6 percent) had received estrogen therapy (mean estima
ted duration of treatment, 5 years). Only women who had taken estrogen
for 7 to 9 years or for 10 or more years had significantly higher bon
e mineral density than women who had not taken estrogen (7 to 9 years
of treatment, P<0.05 at sites in the femur and the spine; greater-than
-or-equal-to 10 years, P<0.05 at all sites except the spine). In the w
omen less than 75 years of age who had taken estrogen for seven or mor
e years, the bone density was, averaging all sites, 11.2 percent great
er than in women who had never received estrogen. Among women 75 years
of age and older in whom the duration of therapy was comparable, bone
density was only 3.2 percent higher than in women who had never taken
estrogen. Conclusions. For long-term preservation of bone mineral den
sity, women should take estrogen for at least seven years after menopa
use. Even this duration of therapy may have little residual effect on
bone density among women 75 years of age and older, who have the highe
st risk of fracture.